The Business of Science Follow XPRIZE’s global Life Sciences competitions Recent NYC MedTech Program XPRIZE at Frankfurt MedTech Program

NYC MedTech Program

Tuesday, October 30th

At the New York office of
McDermott Will & Emery

Registration 5:15 pm

340 Madison Avenue
New York, NY 10173

Company Presentation

Kures, Inc.
Dr. Andrew Kruegal 
President and Cofounder 

CytoDyn Inc

Chief Medical Officer of CytoDyn
Dr. Richard Pestell MD, PhD, MBA, FACP, FRS of Medicine, FRACP 

Keynote Speaker:

Dr Olivier Harari, FRCP, PhD|Vice President Therapeutic Areas|Early Clinical
Development Experimental Sciences|Regeneron Pharmaceuticals Inc.

NYC Medtech will be having its program in association with Invest in Austria and Advantage Austria.

ABA INVEST IN AUSTRIA

ADVANTAGE AUSTRIA

We look forward to seeing you on the evening of October 30th!

If you plan on attending please RSVP, as we have had a overwhelming response to this program.

RSVP HERE – In the subject line, please put your name and company affiliation.

The event will be hosted at 340 Madison Avenue, New York, NY 10173.

RSVP deadline is October 29th. 
Please note, you will receive a confirmation email when your RSVP request has been approved for attendance. 

John will be attending and presenting at Medica, November 11th- 13th. If there are companies or individuals that would be beneficial for you to be contacted please let John know at meeting@nycmedtech.com


NYCMEDTECH Conference May 10th 2018

Reprint from telecareaware

Hungary’s burgeoning med and health tech scene comes to NYC

The NYC MedTech Medical Technology Forum has, for some years, presented programs which bring together the life science, biotech, medical device, and pharma industries. Attendees are always an eclectic mix of executives, reporters, scientists, academics, attorneys, and developers as well as representatives of trade organizations and international partners.

Last week’s presentation at the Consulate General of Hungary provided a view of global health tech rarely seen in the US–the view from Central Europe. It focused on Central European and in particular Hungarian health tech companies, ranging from Big Pharma (Janssen Pharmaceutical/J&J) and law firm Goodwin to six early-stage companies participating in the V4 Connects Global Tour business showcase. The Visegrad Group (the V4) are four Central European countries within the EU–Hungary (this year’s president), Poland, the Czech Republic, and the Slovak Republic–that have worked together since 1991 to promote their regional interests.The evening led off with a discussion panel led by Goodwin’s Frederick Rein, a partner in their IP Litigation Group, with Scott Lassman from their Technology & Life Sciences Group and Peter Takacs, Director Real World Evidence Partnership in the Global Market Access Organization of the Janssen Pharmaceutical Companies of Johnson & Johnson. Most of the discussion was on the differences in drug regulation between the EU and the US, and the swing back in the latter to getting more innovative medical products to US consumers quickly. A hot area is biosimilars, branded drugs that are highly similar but not identical to other drugs, which are gaining FDA approval through the 351(k) pathway. Other topics: the US increasing pressure on pricing and the UK’s Brexit, which will present challenges to drug and device developers from staffing to markets.


Latest News

December 9-12, 2018:
LAHAV

Health Care Technological Innovation
Visit

December 18th, 2018:
NY Health Forum

Yale Club Manhattan, Roof Dining Room & Terrace 22nd FL

Visit

February 2019:
NYCMedtech Program

TBD

June 3-6th 2019:
Bio International

Visit